Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Operating Expenses (2020 - 2025)

Historic Operating Expenses for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $39.6 million.

  • TScan Therapeutics' Operating Expenses rose 1749.87% to $39.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.1 million, marking a year-over-year increase of 2193.78%. This contributed to the annual value of $137.6 million for FY2024, which is 2019.96% up from last year.
  • As of Q3 2025, TScan Therapeutics' Operating Expenses stood at $39.6 million, which was up 1749.87% from $41.7 million recorded in Q2 2025.
  • TScan Therapeutics' 5-year Operating Expenses high stood at $41.7 million for Q2 2025, and its period low was $9.9 million during Q1 2021.
  • Its 5-year average for Operating Expenses is $26.9 million, with a median of $28.6 million in 2023.
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 14465.89% in 2021, then soared by 809.92% in 2024.
  • TScan Therapeutics' Operating Expenses (Quarter) stood at $17.1 million in 2021, then grew by 27.49% to $21.7 million in 2022, then surged by 31.38% to $28.6 million in 2023, then soared by 30.84% to $37.4 million in 2024, then grew by 5.85% to $39.6 million in 2025.
  • Its Operating Expenses was $39.6 million in Q3 2025, compared to $41.7 million in Q2 2025 and $38.4 million in Q1 2025.